Literature DB >> 31466808

A personalized approach to the management of VWD.

Chai W Phua1, Erik Berntorp2.   

Abstract

The goal of treating Von Willebrand Disease (VWD) is to replace deficient or dysfunctional Von Willebrand Factor (VWF) protein. However, the choice of treatment has to be considered carefully in view of patient factors and the unique properties of replacement products. Tailoring a treatment plan to an individual patient's bleeding challenge is an intricate process. This review describes personalization of treatment selection for desmopressin (DDAVP), VWF replacement concentrates, including the newly available recombinant VWF (rVWF) and prophylaxis as a treatment approach in VWD.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Management of von Willebrand Disease; Personalization of von Willebrand Disease; Personalized approach to von Willebrand Disease; Treatment of von Willebrand Disease

Mesh:

Substances:

Year:  2019        PMID: 31466808     DOI: 10.1016/j.transci.2019.08.009

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

Review 1.  Prophylactic management of patients with von Willebrand disease.

Authors:  Massimo Franchini; Omid Seidizadeh; Pier Mannuccio Mannucci
Journal:  Ther Adv Hematol       Date:  2021-12-22

2.  [Interpretation of Chinese guideline on the diagnosis and management of von Willebrand disease (2022)].

Authors:  J Yin; Z Q Yu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

3.  Effectiveness of long-term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease.

Authors:  Lucia Rugeri; Annie Harroche; Yohan Repessé; Dominique Desprez; Brigitte Pan Petesch; Pierre Chamouni; Christine Biron; Birgit Frotscher; Hasan Catovic; Diane Bracquart; Cédric Martin; Marc Trossaërt; Sandrine Meunier; Roseline d'Oiron
Journal:  Eur J Haematol       Date:  2022-04-29       Impact factor: 3.674

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.